Host: The Japanese Society of Toxicology
Progress in anti-cancer drugs, ex. HER2 inhibitor, PD-1/PD-L1 inhibitor, and tyrosine kinase inhibitor targeting cancer driver gene mutation have improved the prognosis of cancer patients in a palliative situation with advanced disease to the post-operative situation with localized disease and also in elderly to the pediatric.
The goal of cancer treatment includes the cure, prolongation of survival time, tumor volume reduction, and last but not least improvement or maintenance of QOL, but some anticancer drugs, including the above mentioned, are known to have some cardiac toxicities, including heart failure, myocarditis, or QT prolongation, these events could deteriorate a patient's QOL especially for patients with the early-stage disease or pediatric patients including AYA generation in a long-term perspective.
To mitigate the risk of drug-induced cardiac toxicities that could be fatal, evaluating potential risk factors to determine the risk-benefit balance in each patient is crucial, alongside other pharmacovigilance activities.
In this presentation, I would introduce our clinical point of view in assessing the efficacy and safety of anti-cancer drugs with cardiac toxicities.
